Patents-Review.com
🔗 Permalink
Inventor profile of:

Paul DELMAR

City:

Basel

Country:

Switzerland

Published Applications:

30

Last publication date:

2014-10-09

Top Assignees for applications by Paul DELMAR

The entities that hold a legal rights for patent applications filed by inventor DELMAR Paul:

Recent patent applications by DELMAR Paul

Paul DELMAR from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2014-10-09
US20140302019A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER

 #2 | 2014-10-02
US20140294811A1
Chemistry; metallurgy

METHOD FOR PREDICTING RISK OF HYPERTENSION ASSOCIATED WITH ANTI-ANGIOGENESIS THERAPY

 #3 | 2014-10-02
US20140294768A1
Chemistry; metallurgy

RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

 #4 | 2014-04-10
US20140099302A1
Physics

METHODS TO IDENTIFY RESPONSIVE PATIENTS

 #5 | 2013-11-28
US20130315899A1
Physics

METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS

 #6 | 2013-08-22
US20130217713A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #7 | 2013-08-22
US20130217712A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #8 | 2013-08-15
US20130210843A1
Chemistry; metallurgy

Predictive marker for EGFR inhibitor treatment

 #9 | 2013-08-01
US20130195857A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER

 #10 | 2013-07-18
US20130183304A1
Physics

NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES

 #11 | 2013-07-18
US20130183303A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

 #12 | 2013-07-18
US20130183302A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

 #13 | 2013-07-18
US20130183301A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER

 #14 | 2013-07-11
US20130177554A1
Physics

NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES

 #15 | 2013-07-04
US20130171134A1
Physics

NEUROPILIN AS A BIOMARKER FOR BEVACIZUMAB COMBINATION THERAPIES

 #16 | 2013-05-16
US20130121999A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER

 #17 | 2013-05-02
US20130108626A1
Physics

BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF PANCREATIC CANCER

 #18 | 2012-08-02
US20120195858A1
Chemistry; metallurgy

RESPONSIVENESS TO ANGIOGENESIS INHIBITORS

 #19 | 2012-06-28
US20120164639A1
Chemistry; metallurgy

METHODS FOR DETECTING LOW GRADE INFLAMMATION

 #20 | 2011-12-22
US20110312981A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #21 | 2011-10-06
US20110245279A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #22 | 2011-09-22
US20110230506A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #23 | 2011-09-08
US20110218212A1
Chemistry; metallurgy

PREDICTIVE MARKERS FOR EGFR INHIBITORS TREATMENT

 #24 | 2011-09-01
US20110212979A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #25 | 2011-08-11
US20110195982A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #26 | 2011-08-04
US20110190321A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #27 | 2011-07-28
US20110184005A1
Chemistry; metallurgy

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #28 | 2011-07-28
US20110184004A1
Human necessities

PREDICTIVE MARKER FOR EGFR INHIBITOR TREATMENT

 #29 | 2011-07-28
US20110182892A1
Human necessities

Methods to identify responsive patients

 #30 | 2011-03-17
US20110064732A1
Physics

METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS
InventorID:

221933 ⎘